Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › GA › Tucker › NPI 1932166386
Lab

Quest Diagnostics Clinical Laboratories INC

Quest Diagnostics Clinical Laboratories INC was paid $211.13M by Medicaid between Jan 2018 and Dec 2024, across 572 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 13% of everything it billed.

33Billing provider infoQUEST DIAGNOSTICS CLINICAL LABORATORIES INC
TUCKER, GA 30084
33aNPI1932166386assigned 04/28/2006
33bProvider typeClinical Medical Laboratory
28Total paid$211.13M
24GClaims19,587,798
24DCodes billed572
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in Georgia

Rank by total paid#1 of 66
Median peer was paid$178K
This provider vs. median1,189×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official TIMMERMAN, LEAH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$2.0M$4.0M$6.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20182,319,047$21.39M
20192,795,715$26.06M
20202,460,289$28.82M
20213,146,913$44.92M
20223,394,050$39.59M
20232,937,005$28.04M
2024incomplete2,534,779$22.31M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 13% 353,884 292,524 $26.58M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 4.8% 355,805 271,796 $10.14M
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 4.5% 546,878 486,243 $9.50M
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 4.3% 538,606 480,059 $9.03M
80050 General health panel 3.5% 380,669 349,621 $7.40M
80061 Lipid panel 3.4% 1,094,431 1,002,858 $7.19M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 3.3% 233,742 177,670 $6.93M
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 3.0% 431,410 389,236 $6.23M
80053 Comprehensive metabolic panel 2.9% 1,269,232 1,144,975 $6.12M
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms 2.8% 156,730 137,953 $5.92M
84443 Thyroid stimulating hormone (TSH) 2.6% 695,339 635,305 $5.52M
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 1.9% 308,255 282,007 $4.05M
560 more codes
85025 Blood count; complete (CBC), automated, and automated differential WBC count 1.8% 950,007 $3.75M
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel 1.8% 7,631 $3.74M
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 1.7% 268,283 $3.52M
83036 Hemoglobin; glycosylated (A1C) 1.6% 745,688 $3.32M
87799 1.3% 122,888 $2.81M
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants 1.3% 7,910 $2.77M
80081 1.3% 65,623 $2.76M
87086 Culture, bacterial; quantitative colony count, urine 1.3% 600,957 $2.73M
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer 1.2% 177,760 $2.53M
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 1.2% 120,583 $2.51M
86003 1.2% 52,364 $2.43M
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 1.1% 127,099 $2.29M
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 66,072 $2.05M
87088 <1% 403,801 $1.85M
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 14,803 $1.84M
82607 <1% 237,622 $1.77M
80074 <1% 75,962 $1.61M
81229 <1% 2,041 $1.58M
86803 <1% 195,296 $1.52M
83655 <1% 192,908 $1.48M
84439 <1% 321,535 $1.46M
81513 <1% 53,761 $1.46M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 43,504 $1.37M
86235 <1% 33,368 $1.37M
82728 <1% 204,413 $1.35M
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed <1% 26,217 $1.26M
87070 <1% 213,876 $1.17M
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 17,342 $1.01M
87512 <1% 48,766 $970K
87902 <1% 9,135 $914K
87186 <1% 190,302 $906K
82746 <1% 127,799 $889K
87077 <1% 192,544 $857K
84403 <1% 65,696 $818K
83550 <1% 187,218 $804K
85027 <1% 243,483 $784K
87522 Neg quan hep c or qual rna <1% 42,422 $754K
83013 <1% 19,933 $748K
86696 <1% 65,662 $742K
86038 <1% 106,488 $716K
88142 <1% 64,052 $709K
83970 <1% 39,940 $704K
80048 Basic metabolic panel (calcium, ionized) <1% 170,670 $698K
83540 <1% 211,329 $678K
36415 Collection of venous blood by venipuncture <1% 588,597 $671K
87081 <1% 162,050 $642K
84481 <1% 73,083 $624K
86480 <1% 24,029 $602K
84153 <1% 72,640 $602K
82670 <1% 38,908 $563K
84702 <1% 79,014 $553K
86592 <1% 233,326 $546K
83001 <1% 52,012 $544K
87340 <1% 105,010 $523K
84146 <1% 41,374 $472K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 5,352 $461K
87536 <1% 12,369 $448K
86695 <1% 56,789 $446K
83002 <1% 42,799 $443K
82570 <1% 182,763 $436K
83880 <1% 27,395 $397K
83735 <1% 115,511 $389K
86376 <1% 50,675 $376K
87480 <1% 31,431 $368K
87510 <1% 29,976 $367K
88141 <1% 31,375 $365K
82784 <1% 45,859 $364K
87660 <1% 31,485 $361K
86665 <1% 19,658 $356K
82105 <1% 41,157 $351K
82652 <1% 23,488 $347K
84144 <1% 30,955 $338K
84436 <1% 107,694 $337K
86364 <1% 17,756 $333K
82043 <1% 156,387 $332K
81511 <1% 6,542 $326K
83525 <1% 50,081 $311K
86140 <1% 114,439 $311K
83516 <1% 55,829 $303K
84402 <1% 26,060 $298K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 8,052 $297K
88307 <1% 3,102 $279K
82785 <1% 28,689 $271K
87650 <1% 19,753 $259K
84480 <1% 36,482 $248K
84479 <1% 86,815 $244K
86769 <1% 6,779 $243K
86200 <1% 34,373 $224K
82627 <1% 18,009 $220K
83021 <1% 20,398 $213K
80076 <1% 50,786 $211K
86704 <1% 35,973 $206K
81001 <1% 131,884 $205K
86706 <1% 37,821 $203K
87147 <1% 61,938 $203K
86039 <1% 33,148 $203K
82677 <1% 14,499 $202K
86160 <1% 17,901 $199K
86431 <1% 65,725 $193K
86762 <1% 26,227 $192K
84681 <1% 20,377 $192K
86787 <1% 22,858 $189K
86708 <1% 29,288 $188K
82950 <1% 65,244 $188K
86008 <1% 9,822 $187K
83690 <1% 53,154 $187K
84270 <1% 16,932 $186K
86225 <1% 24,976 $184K
85652 <1% 123,490 $182K
86800 <1% 22,430 $181K
84550 <1% 77,679 $176K
80164 <1% 25,751 $171K
88312 <1% 4,398 $170K
87563 <1% 11,029 $169K
86147 <1% 12,877 $163K
83520 <1% 27,384 $162K
87481 <1% 20,155 $161K
86664 <1% 17,795 $158K
80055 <1% 6,215 $155K
86336 <1% 14,712 $149K
88342 <1% 6,451 $146K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 3,122 $144K
82533 <1% 16,934 $143K
82248 <1% 52,564 $137K
87075 <1% 26,660 $133K
83020 <1% 17,687 $131K
88185 <1% 491 $130K
86317 <1% 18,751 $130K
86850 <1% 29,127 $128K
82150 <1% 40,141 $126K
82024 <1% 6,830 $125K
86258 <1% 4,669 $118K
86146 <1% 8,285 $114K
81329 <1% 2,384 $113K
81596 <1% 7,638 $113K
85610 <1% 57,945 $110K
87209 <1% 11,613 $106K
88304 <1% 8,292 $105K
86334 <1% 9,862 $104K
87150 <1% 5,781 $104K
82550 <1% 31,396 $99K
80069 <1% 24,636 $95K
86618 <1% 10,600 $94K
87529 <1% 4,549 $92K
86255 <1% 18,168 $92K
84445 <1% 5,100 $91K
84165 <1% 14,508 $90K
82951 <1% 14,550 $87K
88112 <1% 4,658 $85K
86780 <1% 12,203 $83K
85018 <1% 57,581 $83K
87205 <1% 35,771 $83K
83615 <1% 25,131 $81K
84156 <1% 43,204 $81K
86361 <1% 5,984 $79K
82465 <1% 31,688 $78K
80348 <1% 9,624 $78K
86360 <1% 3,835 $78K
87255 <1% 4,391 $75K
87427 <1% 11,916 $73K
82672 <1% 7,106 $72K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 5,322 $72K
87625 <1% 5,361 $72K
84460 <1% 25,493 $72K
85660 <1% 19,708 $71K
84305 <1% 6,664 $71K
81241 <1% 3,471 $71K
83090 <1% 9,616 $70K
85730 <1% 26,274 $69K
87045 <1% 14,464 $67K
82977 <1% 17,082 $66K
83498 <1% 4,280 $65K
84425 <1% 7,958 $65K
88341 <1% 1,429 $63K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 694 $62K
87449 <1% 11,284 $62K
82140 <1% 9,572 $60K
84100 <1% 28,803 $60K
82947 <1% 26,952 $59K
80177 <1% 10,975 $58K
87177 <1% 13,602 $57K
87517 <1% 2,991 $56K
85045 <1% 24,660 $56K
86141 <1% 9,261 $56K
87493 <1% 3,177 $55K
84703 <1% 13,683 $55K
86705 <1% 8,388 $53K
80349 <1% 6,054 $52K
85014 <1% 33,441 $51K
82565 <1% 20,341 $51K
87338 <1% 8,183 $50K
83993 <1% 8,346 $50K
86870 <1% 3,085 $50K
88230 <1% 846 $50K
82274 <1% 6,121 $49K
84450 <1% 19,715 $48K
86757 <1% 2,328 $48K
86341 <1% 7,184 $47K
84154 <1% 6,521 $47K
80361 <1% 4,851 $47K
80346 <1% 4,223 $47K
86617 <1% 3,480 $46K
82247 <1% 17,310 $45K
80197 <1% 7,271 $44K
83921 <1% 6,700 $42K
80185 <1% 5,965 $41K
82310 <1% 17,383 $41K
83630 <1% 4,656 $40K
87101 <1% 7,124 $39K
87329 <1% 5,998 $39K
86900 <1% 24,850 $39K
81240 <1% 2,464 $39K
86901 <1% 24,834 $39K
80178 <1% 11,571 $38K
81243 <1% 1,402 $38K
84207 <1% 3,040 $37K
80355 <1% 4,371 $37K
88262 <1% 592 $37K
86645 <1% 3,909 $37K
82378 <1% 8,409 $36K
87046 <1% 11,172 $36K
84466 <1% 5,616 $36K
86709 <1% 5,671 $36K
84134 <1% 5,507 $36K
82088 <1% 2,415 $35K
82542 <1% 3,873 $35K
86381 <1% 2,665 $35K
86735 <1% 4,334 $34K
86304 <1% 4,391 $34K
87901 <1% 364 $34K
82103 <1% 5,580 $34K
86812 <1% 2,712 $34K
87324 <1% 6,116 $34K
86644 <1% 3,933 $33K
84432 <1% 5,358 $33K
80156 <1% 4,833 $33K
82157 <1% 1,988 $33K
80373 <1% 3,795 $32K
86036 <1% 2,657 $32K
86765 <1% 4,337 $32K
84630 <1% 6,068 $31K
86021 <1% 7,082 $31K
80299 <1% 2,420 $31K
85613 <1% 7,103 $31K
80368 <1% 4,075 $31K
86162 <1% 2,231 $31K
82164 <1% 4,522 $30K
83704 <1% 3,675 $30K
85240 <1% 3,450 $29K
84238 <1% 2,262 $29K
85246 <1% 2,524 $29K
86231 <1% 1,944 $29K
83721 <1% 9,323 $29K
82330 <1% 5,649 $28K
82952 <1% 12,505 $28K
86300 <1% 8,082 $28K
80175 <1% 4,808 $28K
82390 <1% 5,396 $28K
83718 <1% 5,365 $28K
86015 <1% 2,910 $28K
84166 <1% 3,511 $28K
84244 <1% 2,599 $27K
80323 <1% 2,516 $27K
82787 <1% 1,993 $26K
81291 <1% 1,720 $26K
82040 <1% 12,126 $26K
80365 <1% 3,089 $26K
82747 <1% 3,939 $26K
82653 <1% 1,410 $26K
80321 <1% 2,874 $26K
83519 <1% 4,458 $25K
81003 <1% 20,152 $25K
81025 <1% 6,092 $25K
80324 <1% 2,923 $25K
87076 <1% 4,537 $25K
84590 <1% 4,325 $24K
83631 <1% 1,848 $24K
85379 <1% 5,841 $24K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 1,535 $24K
86337 <1% 2,549 $24K
84155 <1% 13,100 $23K
86593 <1% 9,518 $23K
85245 <1% 1,980 $23K
82525 <1% 4,443 $22K
87506 <1% 257 $22K
86301 <1% 3,425 $22K
83521 <1% 2,138 $22K
86359 <1% 1,206 $22K
84520 <1% 10,342 $22K
87900 <1% 364 $21K
82668 <1% 2,603 $21K
80354 <1% 2,538 $21K
86060 <1% 4,633 $21K
87899 <1% 3,252 $21K
85060 <1% 3,303 $20K
86335 <1% 1,987 $20K
86148 <1% 3,385 $20K
87107 <1% 2,645 $20K
86671 <1% 3,841 $20K
83883 <1% 4,383 $20K
85306 <1% 2,782 $20K
80362 <1% 2,625 $20K
87497 <1% 1,190 $19K
82107 <1% 689 $19K
84478 <1% 5,497 $19K
86355 <1% 997 $18K
87800 <1% 1,668 $18K
81015 <1% 10,450 $18K
81256 <1% 954 $18K
86777 <1% 2,090 $18K
87040 <1% 3,406 $17K
83698 <1% 2,633 $17K
85041 <1% 10,258 $17K
87350 <1% 2,721 $16K
84075 <1% 7,132 $16K
85303 <1% 2,676 $16K
80183 <1% 2,627 $16K
86611 <1% 1,838 $16K
83010 <1% 2,938 $16K
83003 <1% 2,734 $16K
82626 <1% 1,319 $15K
80356 <1% 1,462 $15K
85247 <1% 1,342 $15K
80326 <1% 1,486 $15K
84446 <1% 2,379 $15K
82172 <1% 4,650 $15K
80338 <1% 1,514 $15K
86707 <1% 2,148 $15K
86738 <1% 1,812 $14K
88313 <1% 554 $14K
80337 <1% 1,488 $14K
82085 <1% 2,429 $14K
87254 <1% 704 $14K
80370 <1% 1,484 $14K
83835 <1% 1,827 $14K
86308 <1% 4,248 $14K
88184 <1% 507 $13K
88302 <1% 1,186 $13K
80360 <1% 1,373 $13K
87185 <1% 4,143 $13K
84080 <1% 2,141 $12K
80184 <1% 2,174 $12K
82610 <1% 2,086 $12K
80372 <1% 1,343 $12K
85300 <1% 2,403 $12K
80353 <1% 2,007 $12K
80359 <1% 1,262 $12K
82180 <1% 3,085 $12K
87535 <1% 887 $12K
80345 <1% 1,683 $12K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 1,373 $12K
84484 <1% 2,397 $12K
80366 <1% 1,225 $12K
80377 <1% 1,488 $12K
86357 <1% 602 $11K
83014 <1% 2,665 $11K
84132 <1% 4,689 $11K
80051 <1% 2,839 $11K
86778 <1% 1,354 $11K
80364 <1% 1,129 $11K
83695 <1% 3,802 $11K
80367 <1% 1,105 $11K
80344 <1% 1,103 $10K
82397 <1% 1,391 $10K
85598 <1% 1,453 $10K
82530 <1% 1,187 $10K
82104 <1% 1,714 $10K
82239 <1% 1,007 $10K
80159 <1% 1,599 $10K
86666 <1% 755 $9K
86702 <1% 1,563 $9K
87220 <1% 3,167 $9K
87102 <1% 1,978 $9K
80320 <1% 1,386 $9K
80333 <1% 1,102 $9K
85007 <1% 5,397 $9K
86774 <1% 1,193 $9K
86001 <1% 1,142 $9K
84295 <1% 3,526 $8K
80357 <1% 1,172 $8K
80358 <1% 1,857 $8K
84482 <1% 1,097 $8K
87210 <1% 3,578 $8K
82657 <1% 1,179 $8K
83992 <1% 1,651 $8K
82435 <1% 3,207 $7K
81400 <1% 228 $7K
86701 <1% 1,594 $6K
87807 <1% 718 $6K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 83 $6K
82374 <1% 2,958 $6K
87106 <1% 1,053 $6K
84999 <1% 934 $6K
86747 <1% 509 $6K
87206 <1% 1,979 $6K
82175 <1% 703 $6K
83825 <1% 771 $6K
86880 <1% 2,194 $6K
86886 <1% 1,555 $5K
87015 <1% 1,568 $5K
80162 <1% 1,026 $5K
82705 <1% 2,122 $5K
85597 <1% 708 $5K
36416 <1% 7,360 $5K
89055 <1% 2,372 $5K
82232 <1% 728 $5K
83935 <1% 1,550 $5K
88164 <1% 915 $5K
88263 <1% 65 $5K
82384 <1% 413 $5K
83930 <1% 1,372 $5K
87140 <1% 1,072 $5K
86648 <1% 616 $5K
87507 <1% 38 $4K
84163 <1% 506 $4K
80202 <1% 848 $4K
81206 <1% 85 $4K
85305 <1% 754 $4K
85004 <1% 1,649 $4K
80340 <1% 1,101 $4K
87230 <1% 486 $4K
81595 <1% 118 $4K
83951 <1% 177 $4K
82139 <1% 627 $4K
84300 <1% 1,559 $4K
80201 <1% 660 $3K
81510 <1% 149 $3K
82985 <1% 524 $3K
85307 <1% 545 $3K
83605 <1% 527 $3K
82575 <1% 611 $3K
84376 <1% 1,043 $3K
87272 <1% 381 $3K
87425 <1% 436 $3K
80235 <1% 428 $3K
81508 <1% 391 $3K
85302 <1% 465 $3K
82656 <1% 472 $3K
88300 <1% 482 $3K
88173 <1% 47 $3K
85048 <1% 2,691 $3K
81401 <1% 62 $3K
0001M <1% 231 $3K
87634 <1% 78 $3K
88189 <1% 68 $3K
G0476 Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test <1% 561 $2K
82166 <1% 197 $2K
80325 <1% 56 $2K
G0306 Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count <1% 912 $2K
87116 <1% 334 $2K
84597 <1% 343 $2K
0223U <1% 14 $2K
85384 <1% 530 $2K
81599 <1% 625 $2K
87328 <1% 288 $2K
81374 <1% 89 $2K
85049 <1% 1,309 $2K
84140 <1% 249 $2K
84255 <1% 191 $2K
G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision <1% 4,401 $2K
86753 <1% 358 $2K
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) <1% 3,489 $2K
81517 <1% 14 $2K
87631 <1% 37 $2K
81270 <1% 48 $2K
80330 <1% 1,101 $2K
82380 <1% 356 $2K
80195 <1% 258 $2K
84182 <1% 42 $2K
80165 <1% 258 $1K
81257 <1% 37 $1K
G0307 Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count) <1% 664 $1K
83722 <1% 129 $1K
81512 <1% 34 $1K
81381 <1% 29 $1K
82552 <1% 154 $1K
81479 Unlisted molecular pathology procedure <1% 156 $1K
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 9,592 $1K
83876 <1% 100 $1K
82679 <1% 101 $1K
83527 <1% 151 $1K
81000 <1% 381 $1K
82553 <1% 188 $1K
82379 <1% 169 $995.64
86316 <1% 125 $989.95
80374 <1% 99 $980.36
87276 <1% 125 $975.77
80203 <1% 174 $966.64
81403 <1% 12 $935.89
87275 <1% 125 $902.03
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 17 $897.38
86256 <1% 155 $888.47
88311 <1% 296 $840.54
80339 <1% 90 $831.59
G0475 Hiv antigen/antibody, combination assay, screening <1% 796 $828.24
80363 <1% 86 $822.64
82955 <1% 178 $815.00
88360 <1% 13 $792.28
88248 <1% 24 $770.70
80342 <1% 86 $731.14
80332 <1% 86 $705.59
85301 <1% 126 $656.17
88108 <1% 27 $602.85
0014M <1% 12 $600.00
80369 <1% 116 $529.10
87484 <1% 47 $505.32
87906 <1% 12 $481.93
82671 <1% 24 $468.41
89051 <1% 171 $453.22
86215 <1% 64 $447.10
80329 <1% 90 $425.03
81332 <1% 30 $395.32
87468 <1% 42 $392.47
87999 <1% 860 $389.75
87581 <1% 19 $388.76
82365 <1% 54 $385.73
87469 <1% 45 $364.11
86041 <1% 67 $343.26
80335 <1% 52 $334.40
82017 <1% 55 $333.89
86663 <1% 42 $316.78
82340 <1% 115 $299.58
80171 <1% 53 $282.80
89060 <1% 59 $270.58
86152 <1% 12 $269.64
84133 <1% 101 $245.99
84145 <1% 17 $236.92
85670 <1% 95 $235.43
86606 <1% 17 $235.37
83986 <1% 139 $233.97
84206 <1% 29 $233.52
84433 <1% 26 $195.36
86682 <1% 24 $183.78
80230 <1% 15 $179.28
G0123 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision <1% 1,426 $176.86
87280 <1% 32 $171.02
82523 <1% 17 $140.86
85651 <1% 77 $134.57
G0328 Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous <1% 876 $126.51
83625 <1% 27 $125.84
87184 <1% 30 $119.87
83918 <1% 15 $108.84
84252 <1% 13 $108.73
86161 <1% 16 $103.61
86340 <1% 17 $98.36
80352 <1% 13 $95.94
82010 <1% 40 $91.39
83945 <1% 12 $87.19
80371 <1% 13 $80.08
86632 <1% 12 $71.06
82272 <1% 28 $67.21
99199 Unlisted special service, procedure or report <1% 16 $56.24
84540 <1% 45 $44.41
86905 <1% 16 $41.92
84560 <1% 14 $34.39
84311 <1% 13 $31.97
P9604 Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge <1% 18 $30.00
86153 <1% 12 $28.14
99001 0% 203 $0.00
G0124 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician 0% 29 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialTIMMERMAN, LEAH (VICE PRESIDENT)
Parent organizationQUEST DIAGNOSTICS INCORPORATED
Same official

Other billing entities under TIMMERMAN, LEAH

Full network →
ProviderLocationPaid
Unilab CorporationWest Hills, CA$668.50M
Quest Diagnostics IncorporatedClifton, NJ$637.74M
Quest Diagnostics LLC IlWood Dale, IL$429.84M
Quest Diagnostics Clinical Laboratories INCIrving, TX$276.76M
Labone LLCLenexa, KS$212.28M
Quest Diagnostics Clinical Laboratories INCMiramar, FL$197.58M
Labone of Ohio INCCincinnati, OH$167.17M
Unilab CorporationSacramento, CA$141.24M
Quest Diagnostics Incorporated MDBaltimore, MD$121.81M
Quest Diagnostics IncorporatedLas Vegas, NV$59.32M
Quest Diagnostics LLC IlSchaumburg, IL$50.71M
Quest Diagnostics Clinical Laboratories INCTampa, FL$49.99M
Quest Diagnostics Nichols Institute, INC.Chantilly, VA$46.91M
Quest Diagnostics Nichols InstituteSan Juan Capistrano, CA$39.93M
Quest Diagnostics Clinical Laboratories INCNorristown, PA$22.72M
Specialty Laboratories INCWest Hills, CA$16.76M
Quest Diagnostics Clinical Laboratories INCDenver, CO$14.27M
Quest Diagnostics Clinical Laboratories INCHouston, TX$8.76M
Med Fusion, LLCLewisville, TX$4.17M
Quest Diagnostics Clinical Laboratories INCMaryland Heights, MO$2.98M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.